Physician profile
Bronson E Terry
NPI 1225026701
$515.32
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.30 · 2020: $99.69 · 2021: $155 · 2022: $120 · 2023: $38.09 · 2024: $51.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $77.64 | 2019-2020 | |
| Pfizer INC. | $77.14 | 2020-2022 | |
| Neos Therapeutics, Lp | $55.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.05 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $41.85 | 2023-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $39.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.30 | 2019 | |
| Cranial Technologies, INC | $31.71 | 2024 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $22.58 | 2022 | |
| Corium, LLC | $21.81 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $21.42 | 2021 | |
| Kaleo, INC. | $17.68 | 2021 | |
| Neurelis, INC. | $16.22 | 2023 | Valtoco |
| Supernus Pharmaceuticals, INC. | $15.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bronson Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.